r-amphetamine

Small moleculeexperimental

LEVAMFETAMINE the levorotatory form of amphetamine. L-amphetamine, is a central nervous system (CNS) stimulant known to increase wakefulness and concentration in association with decreased appetite and fatigue. Pharmaceuticals that contain levoamphetamine are currently indicated and prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy in some countries. L-Amphetamine succinate was sold in Hungary between 1952 and 1955 under the brand name Cydril. — NCATS

Clinical trial activity

4 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2005 (NCT00150579)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Jan 1, 2005
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Synaptic vesicular amine transporterINHIBITOR
SLC18A2 inhibitor
- Synaptic vesicular amine transporter (SLC18A2) ↗

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](N)Cc1ccccc1

Mol. weight: 135.21 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

l-amphetamine
l-amphetamine
l-amphetamine
levamfetamine
levamfetamine succinate
levamphetamine
levamphetamine
levamphetamine
levamphetamine
levoamphetamine
r-amphetamine

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00202605	Phase 2	Sep 1, 2005	Shire
NCT00152022	Phase 3	Apr 1, 2005	Shire
NCT00152035	Phase 3	Mar 1, 2005	Shire
NCT00150579	Phase 3	Jan 1, 2005	Shire

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Shire	For profit	4	4	2	2005

1 organizations

Page 1 / 1